Tower Research Capital (TRC)’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.21M | Buy |
13,904
+325
| +2% | +$152K | 0.16% | 118 |
|
|
2025
Q4 | $6.16M | Sell |
13,579
-443
| -3% | -$191K | 0.15% | 121 |
|
|
2025
Q3 | $5.49M | Sell |
14,022
-9,456
| -40% | -$3.95M | 0.15% | 112 |
|
|
2025
Q2 | $10.5M | Buy |
23,478
+10,362
| +79% | +$4.78M | 0.28% | 56 |
|
|
2025
Q1 | $6.33M | Sell |
13,116
-7,564
| -37% | -$3.52M | 0.19% | 78 |
|
|
2024
Q4 | $8.33M | Buy |
20,680
+13,516
| +189% | +$6.27M | 0.17% | 89 |
|
|
2024
Q3 | $3.33M | Sell |
7,164
-29,139
| -80% | -$14M | 0.09% | 157 |
|
|
2024
Q2 | $17M | Buy |
36,303
+18,530
| +104% | +$8.04M | 0.29% | 46 |
|
|
2024
Q1 | $7.43M | Sell |
17,773
-27,808
| -61% | -$11.8M | 0.18% | 81 |
|
|
2023
Q4 | $18.5M | Buy |
45,581
+30,175
| +196% | +$11.1M | 0.23% | 77 |
|
|
2023
Q3 | $5.36M | Buy |
15,406
+5,727
| +59% | +$2M | 0.17% | 100 |
|
|
2023
Q2 | $3.41M | Buy |
9,679
+2,835
| +41% | +$955K | 0.11% | 116 |
|
|
2023
Q1 | $2.16M | Sell |
6,844
-2,729
| -29% | -$819K | 0.07% | 184 |
|
|
2022
Q4 | $2.77M | Sell |
9,573
-51,240
| -84% | -$15.6M | 0.11% | 125 |
|
|
2022
Q3 | $17.6M | Buy |
60,813
+13,952
| +30% | +$4.01M | 0.29% | 56 |
|
|
2022
Q2 | $13.2M | Sell |
46,861
-30,636
| -40% | -$8.2M | 0.3% | 56 |
|
|
2022
Q1 | $20.2M | Buy |
77,497
+47,754
| +161% | +$11.3M | 0.19% | 98 |
|
|
2021
Q4 | $6.53M | Buy |
29,743
+3,872
| +15% | +$753K | 0.11% | 152 |
|
|
2021
Q3 | $4.69M | Buy |
25,871
+16,368
| +172% | +$3.2M | 0.12% | 110 |
|
|
2021
Q2 | $1.92M | Sell |
9,503
-21,931
| -70% | -$4.59M | 0.05% | 323 |
|
|
2021
Q1 | $6.75M | Buy |
31,434
+24,782
| +373% | +$5.44M | 0.11% | 156 |
|
|
2020
Q4 | $1.57M | Sell |
6,652
-7,344
| -52% | -$1.69M | 0.05% | 307 |
|
|
2020
Q3 | $3.81M | Buy |
13,996
+8,388
| +150% | +$2.31M | 0.04% | 127 |
|
|
2020
Q2 | $1.63M | Buy |
5,608
+5,495
| +4,863% | +$1.49M | 0.07% | 294 |
|
|
2020
Q1 | $27K | Sell |
113
-784
| -87% | -$180K | ﹤0.01% | 1581 |
|
|
2019
Q4 | $196K | Sell |
897
-4,736
| -84% | -$958K | 0.02% | 599 |
|
|
2019
Q3 | $955K | Buy |
+5,633
| New | +$997K | 0.07% | 302 |
|
|
2019
Q2 | – | Sell |
-6,247
| Closed | -$1.15M | – | 4358 |
|
|
2019
Q1 | $1.15M | Buy |
6,247
+5,322
| +575% | +$983K | 0.07% | 236 |
|
|
2018
Q4 | $153K | Sell |
925
-790
| -46% | -$137K | 0.01% | 783 |
|
|
2018
Q3 | $331K | Sell |
1,715
-10,919
| -86% | -$1.94M | 0.02% | 706 |
|
|
2018
Q2 | $2.15M | Buy |
12,634
+12,468
| +7,511% | +$1.93M | 0.12% | 156 |
|
|
2018
Q1 | $27K | Sell |
166
-371
| -69% | -$60.6K | ﹤0.01% | 2023 |
|
|
2017
Q4 | $81K | Sell |
537
-1,852
| -78% | -$274K | 0.01% | 1002 |
|
|
2017
Q3 | $363K | Buy |
2,389
+2,247
| +1,582% | +$338K | 0.03% | 384 |
|
|
2017
Q2 | $18K | Buy |
142
+141
| +14,100% | +$17K | ﹤0.01% | 1282 |
|
|
2017
Q1 | $0 | Sell |
1
-6,722
| -100% | -$592K | ﹤0.01% | 3976 |
|
|
2016
Q4 | $495K | Buy |
6,723
+3,006
| +81% | +$245K | 0.05% | 347 |
|
|
2016
Q3 | $324K | Buy |
3,717
+3,179
| +591% | +$300K | 0.03% | 281 |
|
|
2016
Q2 | $46K | Sell |
538
-1,009
| -65% | -$87.2K | ﹤0.01% | 1621 |
|
|
2016
Q1 | $123K | Buy |
1,547
+1,225
| +380% | +$111K | 0.02% | 446 |
|
|
2015
Q4 | $41K | Buy |
+322
| New | +$38.9K | 0.01% | 678 |
|
|
2015
Q3 | – | Sell |
-703
| Closed | -$87K | – | 4836 |
|
|
2015
Q2 | $87K | Sell |
703
-6,073
| -90% | -$765K | 0.01% | 956 |
|
|
2015
Q1 | $799K | Buy |
6,776
+6,316
| +1,373% | +$757K | 0.1% | 127 |
|
|
2014
Q4 | $55K | Sell |
460
-184
| -29% | -$20.7K | 0.01% | 978 |
|
|
2014
Q3 | $72K | Buy |
+644
| New | +$61.3K | 0.01% | 1243 |
|
|
2014
Q1 | – | Sell |
-6,473
| Closed | -$481K | – | 4981 |
|
|
2013
Q4 | $481K | Sell |
6,473
-3,574
| -36% | -$249K | 0.08% | 190 |
|
|
2013
Q3 | $761K | Buy |
+10,047
| New | +$799K | 0.08% | 221 |
|
Other funds holding VRTX
VCM
VPM
Tower Research Capital (TRC)'s VRTX Position: Q1 2026 in Review
Tower Research Capital (TRC) increased its Vertex Pharmaceuticals (VRTX) stake by 2.4% in Q1 2026, buying an estimated $152K and bringing the position to 13,904 shares worth $6.21M. The position accounts for 0.16% of the portfolio, ranked #118.
Tower Research Capital (TRC) first reported a position in VRTX in Q3 2013 and has held it in 47 quarters since. The position peaked at $20.2M in Q1 2022. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Tower Research Capital (TRC) held 13,904 shares of Vertex Pharmaceuticals worth $6.21M as of Q1 2026.
- Tower Research Capital (TRC) bought 325 Vertex Pharmaceuticals shares in Q1 2026, an estimated $152K.
- Vertex Pharmaceuticals made up 0.16% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #118 holding.
- Tower Research Capital (TRC) first reported a position in Vertex Pharmaceuticals in Q3 2013 and has held it in 47 quarters since.
- Tower Research Capital (TRC)'s Vertex Pharmaceuticals position peaked at $20.2M in Q1 2022.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.